By Administrator_India
Japan’s health ministry has approved dexamethasone, a cheap and widely used steroid, as a second treatment of COVID-19 after a trial in Britain showed the drug reduced death rates in hospitalised patients.
The ministry included dexamethasone as an option for treatment along with Gilead Sciences Inc’s antiviral drug remdesivir in a recent revision to its handbook.
Shares of Nichi-Iko Pharmaceutical Co, among those that produce the drug, gained as much as 6.5% in early trade.
In results announced last month, a trial by researchers in the United Kingdom showed dexamethasone as the first drug to save lives of COVID-19 patients in what scientists said was a major breakthrough in the coronavirus pandemic.
The full results of the large randomised clinical trial released last Friday in the New England Journal of Medicine confirmed the benefits for people with advanced or moderate disease.
The market is expected to open in the red as trends in SGX Nifty indicate a negative opening for the Read more
By Administrator_India Capital Sands Japan may be ready for a snap election after the ruling party picks a new leader Read more
By Administrator_India Capital Sands Japan's exports likely tumbled at a double-digit pace for the fourth month in a row in Read more
By Administrator_India Capital Sands Japanese researchers confirmed the presence of the coronavirus in wastewater plants, a finding that could serve Read more